CHA
REGN icon

Carmichael Hill & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Carmichael Hill & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5
Closed -$3K – 733
2020
Q2 		$3K Hold
5
– – ﹤0.01% 612
2020
Q1 		$2K Buy
+5
New +$2.06K ﹤0.01% 622

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Carmichael Hill & Associates's REGN Position: Q3 2020 in Review

Carmichael Hill & Associates sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 5 shares — an estimated $3K sold.

Carmichael Hill & Associates first reported a position in REGN in Q1 2020 and held it in 2 quarters. The position peaked at $3K in Q2 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

  • Carmichael Hill & Associates reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Carmichael Hill & Associates sold 5 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $3K.
  • Carmichael Hill & Associates first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Carmichael Hill & Associates's Regeneron Pharmaceuticals position peaked at $3K in Q2 2020.
  • 907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on Carmichael Hill & Associates's 13F filing for Q3 2020, filed 12 Nov 2020.